Diffuse cutaneous systemic sclerosis following SARS-Co V-2 vaccination.
J Autoimmun
; 128: 102812, 2022 04.
Article
in English
| MEDLINE | ID: covidwho-1712743
ABSTRACT
The largest world-wide vaccination rollout ever is currently underway to tackle the covid-19 pandemic. We report a case of diffuse cutaneous systemic sclerosis (SSc) in a 70-year-old male with rapidly progressive skin thickening which developed two weeks after receiving the first dose of the ChAdOx1 nCOV-19 vaccine. As the onset of SSc skin was in close temporal proximity to the administration of the first dose vaccine with no other triggers, we suspected a possible adverse reaction to the ChAdOx1 nCOV-19 vaccine. We hypothesise that the recombinant adenoviral vector encoding the spike protein antigen of SARS-CoV-2 triggered an unexpected immune activation resulting in an atypical presentation of late-onset SSc, within the well-recognised ANA positive, ENA negative subgroup of patients.We review the possible mechanisms underlying autoimmunity when provoked by vaccination and other published rheumatological phenomenon occurring shortly after COVID vaccination.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Scleroderma, Diffuse
/
COVID-19
Type of study:
Case report
/
Observational study
Topics:
Vaccines
Limits:
Aged
/
Humans
/
Male
Language:
English
Journal:
J Autoimmun
Journal subject:
Allergy and Immunology
Year:
2022
Document Type:
Article
Affiliation country:
J.jaut.2022.102812
Similar
MEDLINE
...
LILACS
LIS